Promosome v BioNTech (CFI, 3 April 2025)
| Date | 3 April 2025 |
|---|---|
| Court | CFI |
| Division | Munich (DE) Local Division |
| Type of action | Procedural Order |
| Registry reference | App_11376/2025 · ORD_11610/2025 |
| Parties | BioNTech Manufacturing Marburg GmbH , BioNTech Manufacturing GmbH , BioNTech SE, BioNTech Europe GmbH , BioNTech Innovative Manufacturing S… |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 3 April 2025 (UPC_CFI_846/2024, ORD_11610/2025 and ORD_11611/2025), Judge-rapporteur Kupecz of the Munich Local Division rejected the applications to produce evidence filed on 7 March 2025 by the five BioNTech companies and the four Pfizer companies, defendants to Promosome LLC’s infringement action on EP 2 401 365. They sought, under penalty, the detailed materials and methods and the raw data behind the qPCR experiments in Exhibit VB 6. A single document decides both applications (Nos 11376/2025 and 11372/2025), which were identical in substance.
Question
May a party obtain, under Rule 190 RoP, the raw data behind experiments relied on by its opponent without first contesting the facts those experiments establish?
Decision
The defendants did not state which fact they intended to prove, had not specifically contested the facts drawn from Exhibit VB 6 or raised concrete defences the evidence would support, a prior step under Rule 24(e) to (g) RoP, and offered no reasonably available and plausible evidence for their defence. Whether the evidence was sufficiently specified under Rule 190.1 RoP was doubtful but left open. The front-loaded nature of the proceedings does not oblige the claimant to file all underlying data at this stage, since the parties determine their own evidence (Art. 43 UPCA). Production may still be ordered later (Rules 190 and 172.2 RoP) or clarification sought (Rule 9.1 RoP). The penalty request fell with the main request. Panel review remains available (Rule 333 RoP).
Key points for practice
- Practical point: an application to produce evidence must follow a specific denial of the facts and a concrete defence, without them it is inadmissible or, in any event, unfounded.
Provisions applied
- Agreement on a Unified Patent Court
- Arts 43, 59(1) and 82(4)
- Rules of Procedure
- Rules 9.1, 24, 172.2, 190.1 and 333
- Directive 2004/48/EC
- Art. 6(1)
- Case law cited
- Guangdong OPPO v Panasonic, Court of Appeal, 24 September 2024, Winnow Solutions v Orbisk, The Hague Local Division, 14 October 2024, Dish v Aylo, Mannheim Local Division, 20 October 2024
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Written procedure (UPC), Court fees and costs (UPC).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimantBioNTech Manufacturing GmbH8 decisions in the corpusFollow this party
- claimantBioNTech SE6 decisions in the corpusFollow this party
- claimantBioNTech Europe GmbH3 decisions in the corpusFollow this party
- claimantBioNTech Manufacturing Marburg GmbH4 decisions in the corpusFollow this party
- claimantBioNTech Innovative Manufacturing S2 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Procedural Order
- Outcome (Dhenne Avocats summary)
- Les demandes de BioNTech et Pfizer tendant à la production des données brutes des expériences qPCR de Promosome sont rejetées comme irrecevables ou, en tout cas, mal fondées.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 2 401 365mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Winnow Solutions v Orbisk (CFI, 14 October 2024) cited in this record
- Guangdong OPPO Mobile Telecomm v Panasonic (CoA, ORD_48652/2024, 24 September 2024) cited in this record
- Pfizer v Promosome (CFI, 3 April 2025) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 401 365Reengineering mrna primary structure for enhanced protein production recorded proprietor: Scripps Research Institute | Mentioned in the analysis (role not qualified) Also mentioned in 6 other decision(s): Promosome v BioNTech (CFI, UPC_CFI_846/2024, 7 July 2026) · Promosome v BioNTech (CFI, 15 July 2025) · Promosome v BioNTech (CFI, 17 April 2025) · Promosome v BioNTech (CFI, 9 April 2025) · Promosome v BioNTech (CFI, 10 March 2025) · Promosome v BioNTech (CoA, 12 October 2026) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.